Known drug space as a metric in exploring the boundaries of drug-like chemical space

European Journal of Medicinal Chemistry

Volumn 44, Issue 12, 2009, Pages 5006-5011

  Mirza, Amin ^a   Desai, Radha ^b   Reynisson, Jóhannes ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Aryl amines; Aryl nitro; Carcinogens; Drug like chemical space; Halogen atoms and drug development discovery; Known drug space; Marketed drug compounds; Nitrenium ions; Sulphur atoms

Indexed keywords

AROMATIC AMINE; HALOGEN; NITRO DERIVATIVE; SULFUR DERIVATIVE;

ARTICLE; BIOCHEMICAL COMPOSITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; DRUG SPACE; DRUG STRUCTURE; ELIMINATION REACTION;

DRUG ADMINISTRATION ROUTES; DRUG DESIGN; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS;

EID: 70449674250     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.08.014     Document Type: Article

References (62)

1. Egan W.J., Walters W.P., and Murcko M.A. Curr. Opin. Drug Discov. Devel. 5 (2002) 540-549
2. Davis A.M., Keeling D.J., Steele J., Tomkinson N.P., and Tinker A.C. Curr. Top. Med. Chem. 5 (2005) 421-439
3. Lajiness M.S., Vieth M., and Erickson J. Curr. Opin. Drug Dis. Dev. 7 4 (2004) 470-477
4. Oprea T.I., Bologa C., and Olah M. In: Alvarez J., and Shoichet B.K. (Eds). Virtual screening in drug discovery (2005), Taylor & Francis, Boca Raton pp. 89-106
5. Lipinski C.A., and Pharmacol J. Toxicol Meth 44 (2000) 235-249
6. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Deliv. Rev. 23 (1997) 3-25
7. Palm K., Stenberg P., Luthman K., and Artursson P. Pharm. Res. 14 (1997) 568-571
8. Veber D.F., Johnson S.R., Cheng H., Smith B.R., Ward K.W., and Kopple K.D. J. Med. Chem. 45 (2002) 2615-2623
9. Wenlock M.C., Austin R.P., Barton P., Davis A.M., and Leeson P.D. J. Med. Chem. 46 (2003) 1250-1256
10. Lu J.J., Crimin K., Goodwin J.T., Crivori P., Orrenius C., Xing L., Tandler P.J., Vidmar T.J., Amore B.M., Wilson A.G.E., Stouten P.F.W., and Burton P.S. J. Med. Chem. 47 (2004) 6104-6107
11. G.M. Rishton, DDT 2:1997;382-384.
12. G.M. Rishton, DDT 8:2003;86-96.
13. McGovern S.L. In: Alvarez J., and Shoichet B.K. (Eds). Virtual screening in drug discovery (2005), Taylor & Francis, Boca Raton 107-123
14. McGovern S.L., Caselli E., Grigorieff N., and Schoichet B.K. J. Med. Chem. 45 (2002) 1712-1722
15. McGovern S.L., Helfand B.T., Feng B., and Schoichet B.K. J. Med. Chem. 46 (2003) 4265-4272
16. Roche O., Schneider P., Zuegge J., Guba W., Kansy M., Alanine A., Bleicher K., Danel F., Gutknecht E.M., Rogers-Evans M., Neidhart W., Stalder H., Dillon M., Sjögren E., Fotouhi N., Gillespie P., Goodnow R., Harris W., Jones P., Taniguchi M., Tsujii S., von der Saal W., Zimmermann G., and Schneider G. J. Med. Chem. 45 (2002) 137-142
17. Feng Y.B., Shelat A., Doman N.T., Guy R.K., and Shoichet K.B. Nat. Chem. Bio. 1 (2005) 146-148
18. Later D.W., Pelroy R.A., Stewart D.L., McFall T., Booth G.M., Lee M.L., Tedjamulia M., and Castle R.N. Environ. Mutagen 6 (1984) 497-515
19. Kadlubar F.F., and Beland F.A. In: Harvey R.G. (Ed). Polycyclic hydrocarbons and carcinogenesis (1985), American Chemical Society, Washington, D.C 341-370
20. Kadlubar F.F., Miller J.A., and Miller E.C. Cancer Res. 37 (1977) 805-814
21. Sinclair J.C., Sandy J., Delgoda R., Sim E., and Noble M.E.M. Nat. Struct. Biol. 7 (2000) 560-564
22. Josephy P.D., Summerscales J., DeBruin L.S., Schlaeger C., and Ho J. Biol. Chem. 383 (2002) 977-982
23. Carroll C.C., Warnakulasuriyarachchi D., Nokhbeh M.R., and Lambert I.B. Mutat. Res. 501 (2002) 79-98
24. Arlt V.M., Stiborova M., Henderson C.J., Osborne M.R., Bieler C.A., Frei E., Martinek V., Sopko B., Wolf R., Schmeiser H.H., and Phillips D.H. Cancer Res. 65 (2005) 2644-2652
25. Boffetta P., and Nyberg F. Br. Med. Bull. 68 (2003) 71-94
26. Vineis P., Forastiere F., Hoek G., and Lipsett M. Int. J. Cancer 111 (2004) 647-652
27. Kerr J.A. Chem. Rev. 66 (1966) 465-500
28. McMillen D.F., and Golden D.M. Annu. Rev. Phys. Chem. 33 (1982) 493-532
29. Kyriacou D. Modern Electroorganic Chemistry (1994), Springer-Verlag, Berlin pp. 74-78
30. Parker V.D. In: Baizer M.M. (Ed). Organic Electrochemistry, An Introduction and a Guide (1973), Marcel Dekker, Inc., New York 551-559
31. Ethanol has an Ionisation potential (IP) of 10.5 eV vs. 9.3 eV for ethanethiol and diethyl ether has an IP of 9.5 vs. 8.4 for diethylsulphide [32].
32. National Institute of Standards and Technology. //webbook.nist.gov/chemistry//
33. The measured Log P of benzene is 2.1 ± 0.1, fluorobenzene is 2.3 ± 0.2, chlorobenzene 2.8 ± 0.2, bromobenzene 3.0 ± 0.2, and finally iodobenzene 3.3 ± 0.2 [34]. Lipophilicity is clearly increased upon halogenation even though the dipole moment, which offsets this effect, is also increased by ∼1.7 Debye in all cases [35].
34. Sangster J. J. Phys. Chem. Ref. Data 18 (1989) 1111-1229
35. Stewart J.J.P. J. Comp. Chem. 10 (1989) 221-264
36. Oprea T.I., Davis A.M., Teague S.J., and Leeson P.D. J. Chem. Inf. Comput. Sci. 41 (2001) 1308-1315
37. This has led to the introduction of the concept of lead-like chemical space where the molecular descriptors used generally have lower cut-off values than for drug-like chemical space [38,39].
38. Teague S.J., Davis A.M., Leeson P.D., and Oprea T.I. Ange. Chem. Int. Ed. 38 (1999) 3743-3748
39. Oprea T.I. Mol Divers 5 (2000) 199-208
40. Ioakimidis L., Thoukydidis L., Naeem S., Mirza A., and Reynisson J. QSAR Comb. Sci. 27 (2008) 445-456
41. Axerio-Cilies P., Castañeda I.P., Mirza A., and Reynisson J. Eur. J. Med. Chem. 44 (2009) 1128-1134
42. Overington J.P., Al-Lazikani B., and Hopkins A.L. Nat. Rev. Drug. Discov. 5 (2006) 993-996
43. Agüero F., Al-Lazikani B., Aslett M., Berriman M., Buckner F.S., Campbell R.K., Carmona S., Carruthers I.M., Chan A.W.E., Chen F., Crowther G.J., Doyle M.A., Hertz-Fowler C., Hopkins A.L., McAllister G., Nwaka S., Overington J.P., Pain A., Paolini G.V., Pieper U., Ralph S.A., Riechers A., Roos D.S., Sali A., Shanmugam D., Suzuki T., Van Voorhis W.C., and Verlinde C.L.M.J. Nat. Rev. Drug. Discov. 7 (2008) 900-907
44. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., and Woolsey J. Nucleic Acids Res. 34 (2006) D668-D672
45. Singh R., Manjunatha U., Boshoff H.I.M., Ha Y.H., Niyomrattanakit P., Ledwidge R., Dowd C.S., Lee I.Y., Kim P., Zhang L., Kang S., Keller T.H., Jiricek J., and Barry III C.E. Science 322 (2008) 1392-1395
46. Novak M., and Rajagopal S. Chem. Res. Toxicol 15 (2002) 1495-1503
47. Nguyen T., and Novak M. J. Org. Chem. 72 (2007) 4698-4706
48. Arlt V.M., Glatt H., Gamboa da Costa G., Reynisson J., Takamura-Enya T., and Phillips D.H. Toxicol Sci. 98 (2007) 445-457
49. Reynisson J., Stiborová M., Martínek V., Gamboa da Costa G., Phillips D.H., and Arlt V.M. Environ. Mol. Mutagen. 49 (2008) 659-667
50. Borosky G.L. Chem. Res. Toxicol 20 (2007) 171-180
51. Borosky G.L., and Mol J. Graph. Models 27 (2008) 459-465
52. These include aliphatic thioesters, sulphonate esters, sulphur-sulphur single bonds, nitrogen-sulphur single bonds, thioureas, thiols, and thiazolidine-2,4-diones [11,12,41].
53. Koch W., and Holthausen M.C. A Chemist's Guide to Density Functional Theory (1999), Wiley-VCH, Weinheim pp. 137-176
54. Tschumper G.S., and Schaefer H.F. J. Chem. Phys. 107 (1997) 2529-2541
55. Curtiss L.A., Redfern P.C., Raghavachari K., and Pople J.A. J. Chem. Phys. 109 (1998) 42-55
56. Vera D.M., and Pierini A.B. Phys. Chem. Chem. Phys. 6 (2004) 2899-2903
57. Reynisson J., and Steenken S. Org. Biomol. Chem. 2 (2004) 578-584
58. The possibility of difficult synthetic routes and metabolic instability of compounds containing bromine and iodine can also play a role.
59. Kauffman G.B. J. Chem. Educ. 56 (1979) 454-455
60. Lajiness M.S., Maggiora G.M., and Shanmugasundaram V. J. Med. Chem. 47 (2004) 4891-4896
61. Kola I., and Landis J. Nat. Rev. Drug Discov. 3 (2004) 711-716
62. Schuster D., Laggner C., and Langer T. Curr. Pharm. Des 11 (2005) 3545-3560